Drug intelligence / Profile preview

triptorelinumab

Development stage: Preclinical
Lead developer: Beijing Tsinghua Changgung Hospital
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

Triptorelinumab is an investigational monoclonal antibody currently being evaluated in clinical trials for various cancers. It is being studied in combination with axitinib for the treatment of mucosal melanoma and in combination with lenvatinib and radiotherapy for the neoadjuvant treatment of intrahepatic cholangiocarcinoma. While its precise mechanism of action and specific target have not been explicitly identified in publicly available information, its classification as a monoclonal antibody and its use in combination with other immunotherapies and targeted therapies suggest it likely functions as an immunotherapeutic agent or a targeted therapy in oncology.

Beyond the preview

Go deeper on triptorelinumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on triptorelinumab.

Explore the full profile